FierceBiotech 2. März 2026 Roche reports another phase 3 multiple sclerosis win, but deaths add to safety questions
FierceBiotech 28. Feb. 2026 BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival
FierceBiotech 27. Feb. 2026 Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates
FierceBiotech 27. Feb. 2026 Lilly debuts Nvidia supercomputer with fanfare and focus on escaping traditional pharma lifecycle
FierceBiotech 27. Feb. 2026 FDA slams ExThera with warning letter over controversial blood filter device
FierceBiotech 27. Feb. 2026 As CAR-T cell therapy gains ground on solid tumors, regulatory red tape hinders progress
FierceBiotech 27. Feb. 2026 'Like talking to a brick wall': Senate hearing takes aim at FDA's rare disease review process
FierceBiotech 26. Feb. 2026 Sarepta CEO Doug Ingram to retire after a decade of Duchenne breakthroughs and controversies
FierceBiotech 26. Feb. 2026 Analysts see potential in MDMA drug after AtaiBeckley reports improvements in anxiety trial
FierceBiotech 26. Feb. 2026 Boehringer pens $500M pact with British biotech for oral approach to autoimmune diseases
FierceBiotech 26. Feb. 2026 Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial
FierceBiotech 26. Feb. 2026 Quantum Surgical snaps up J&J's NeuWave Medical for its microwave ablation technology
FierceBiotech 26. Feb. 2026 Protagonist plans to pocket $400M from Takeda rather than split US rusfertide profits